Linked Life Data

18007548

Source:http://linkedlifedata.com/resource/pubmed/id/18007548

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
2007-11-16
pubmed:abstractText
The treatment of autoimmune hepatitis is evolving as the natural history of the disease and newer agents become available. This concise review will outline the various treatment options in these patients. Treatment with current corticosteroids and azathioprine works in most patients but issues of intolerance and incomplete response arise. These situations led to the investigation of newer immunosupressants including mycophenolate mofetil, budesonide cyclosporine, tacrolimus and ursodeoxycholic acid. The newer agents have been studied in small patient numbers so they are not first-line treatment yet but do have a clear role in those patients with intolerance of incomplete response to standard corticosteroids and azathioprine.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
1665-2681
pubmed:author
pubmed:issnType
Print
pubmed:volume
6
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
204-7
pubmed:meshHeading
pubmed:articleTitle
The medical treatment for autoimmune hepatitis through corticosteroid to new immunosuppressive agents: a concise review.
pubmed:affiliation
Department of Internal Medicine, Division of Gastroenterology and Hepatology, University of Texas Medical Branch. Galveston, Texas 77573-0764, USA.
pubmed:publicationType
Journal Article, Review